Melanoma antigen recognized by T cells 1 peptide–Human leukocyte antigen class II complex (MART-1–HLA class II complex)

The Melanoma antigen recognized by T cells 1 (MART-1) peptide–Human leukocyte antigen (HLA) class II complex is a molecular assembly formed by the binding of a MART-1-derived peptide into the peptide-binding groove of an HLA class II molecule, typically HLA-DR (Zarour et al., 2000, J Exp Med). MART-1, also known as Melan-A, is a melanocyte differentiation antigen that is highly expressed in the majority of melanomas, making it a significant target for immunotherapy (Touloukian et al., 2000, J Immunol). While MART-1 is most frequently studied in the context of HLA class I presentation to CD8+ T cells, the HLA class II complex is essential for the activation of CD4+ T cells, which play a critical role in providing assistance for cytotoxic responses and maintaining long-term anti-tumor immunity (Topalian et al., 1994, PNAS). Therapeutic strategies targeting this complex include peptide vaccines and T-cell receptor (TCR) engineered T-cell therapies designed to recognize the specific peptide-MHC interface (Chamoto et al., 2004, Cancer Res). A primary safety concern with targeting MART-1 is on-target off-tumor toxicity, as the antigen is also expressed in normal melanocytes in the skin, eye, and inner ear. This can lead to clinical manifestations such as vitiligo, uveitis, or autoimmune hearing loss, which represent significant therapeutic challenges in the development of MART-1-directed therapies (Johnson et al., 2009, Blood).

Other names

Melan-A peptide–MHC class II complexMART-1–HLA-DR complexMART-1–HLA-DQ complexMelan-A–HLA class II complex

Recognition by specific T-cell receptors (TCRs) on CD4+ T cells, leading to cytokine production and coordination of the anti-tumor immune response.